Milne Christopher-Paul, Kaitin Kenneth I
Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, United States.
Front Pharmacol. 2019 Mar 8;10:144. doi: 10.3389/fphar.2019.00144. eCollection 2019.
A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for innovative new medicines to treat a range of both infectious and non-communicable diseases, while containing spiraling healthcare costs. The challenge is particularly great in therapeutic areas where, despite significant medical need and economic impact, the technical challenges and commercial risk of development serve as disincentives to drug sponsors. These areas include cardiovascular diseases as well as diseases and disorders of the central nervous system. Currently, the development and approval of new active substances, with its disproportionate focus on oncology, is not in alignment with healthcare needs in most geographic regions. In this article, we discuss the origins of this misalignment and suggest various approaches to address healthcare needs going forward.
全球医疗保健当局面临着诸多挑战。首要挑战是需要创新型新药来治疗一系列传染病和非传染病，同时控制不断攀升的医疗成本。在一些治疗领域，这一挑战尤为严峻，尽管存在重大医疗需求和经济影响，但开发的技术挑战和商业风险阻碍了制药商的积极性。这些领域包括心血管疾病以及中枢神经系统疾病和障碍。目前，新活性物质的开发和审批过度集中于肿瘤学，与大多数地理区域的医疗需求不一致。在本文中，我们将探讨这种不一致的根源，并提出应对未来医疗需求的各种方法。
